Page 104 - Demo

Chapter 410222. Serra I, Scheldeman C, Bazelot M, Whalley BJ, Dallas ML, de Witte PAM, et al. Cannabidiol modulates phosphorylated rpS6 signalling in a zebrafish model of Tuberous Sclerosis Complex. Behav Brain Res. 2019; 23. Valstar MJ, Neijs S, Bruggenwirth HT, Olmer R, Ruijter GJG, Wevers RA, et al. Mucopolysaccharidosis type IIIA: Clinical spectrum and genotype-phenotype correlations. Ann Neurol. 2010.24. Poorthuis BJHM, Wevers RA, Kleijer WJ, Groener JEM, De Jong JGN, Van Weely S, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet. 1999;105(1–2). 25. Warmerdam HAG, Termeulen-Ferreira EA, Tseng LA, Lee JY, van Eeghen AM, Ferreira CR, et al. A Scoping Review of Inborn Errors of Metabolism Causing Progressive Intellectual and Neurologic Deterioration (PIND). Front Neurol. 2020;10. 26. Valstar MJ, Ruijter GJG, van Diggelen OP, Poorthuis BJ, Wijburg FA. Sanfilippo syndrome: A mini-review. Journal of Inherited Metabolic Disease. 2008. 27. Schuchman EH, Ledesma MD, Simonaro CM. New paradigms for the treatment of lysosomal storage diseases: targeting the endocannabinoid system as a therapeutic strategy. Vol. 16, Orphanet Journal of Rare Diseases. 2021. 28. Hagerman RJ, Berry-Kravis E, Hazlett HC, Bailey DB, Moine H, Kooy RF, et al. Fragile X syndrome. Vol. 3, Nature reviews. Disease primers. 2017. 29. Khandjian EW, Robert C, Davidovic L. FMRP, a multifunctional RNA-binding protein in quest of a new identity. Front Genet. 2022;13:2035. 30. Jung KM, Sepers M, Henstridge CM, Lassalle O, Neuhofer D, Martin H, et al. Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nat Commun. 2012;3. 31. Laprairie RB, Bagher AM, Kelly MEM, Denovan-Wright EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015;172(20). 32. Gupta S, Faughnan ME, Tomlinson GA, Bayoumi AM. A framework for applying unfamiliar trial designs in studies of rare diseases. Journal of Clinical Epidemiology. 2011. 33. Tate RL, Perdices M. Single-Case Experimental Designs for Clinical Research and Neurorehabilitation Settings. Single-Case Experimental Designs for Clinical Research and Neurorehabilitation Settings. 2019. 34. Bradbury J, Avila C, Grace S. Practice-Based Research in Complementary Medicine: Could N-of-1 Trials Become the New Gold Standard? Healthcare. 2020.35. OCEBM Levels of Evidence Working Group, Jeremy Howick, Iain Chalmers (James Lind Library), Paul Glasziou, Trish Greenhalgh, Carl Heneghan, Alessandro Liberati, Ivan Moschetti, Bob Phillips, Hazel Thornton OG and MH. The Oxford levels of Evidence 2. Oxford Cent Evidence-Based Med. 2011.36. Guyatt G, Sackett D, Adachi J, Roberts R, Chong J, Rosenbloom D, et al. A clinician’s guide for conducting randomized trials in individual patients. CMAJ. 1988.37. Shamseer L, Sampson M, Bukutu C, Schmid CH, Nikles J, Tate R, et al. CONSORT extension for reporting N-of-1 trials (CENT) 2015: Explanation and elaboration. BMJ. 2015.38. OCEBM Levels of Evidence Working Group, Durieux N, Pasleau F, Howick J. The Oxford 2011 Levels of Evidence. Group. 2011.39. Porcino AJ, Shamseer L, Chan AW, Kravitz RL, Orkin A, Punja S, et al. SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist. BMJ. 2020.40. Stunnenberg BC, Raaphorst J, Groenewoud HM, Statland JM, Griggs RC, Woertman W, et al. Effect of Mexiletine on Muscle Stiffness in Patients with Nondystrophic Myotonia Evaluated Using Aggregated N-of-1 Trials. JAMA - J Am Med Assoc. 2018;320(22). 41. Blackston J, Chapple A, McGree J, McDonald S, Nikles J. Comparison of Aggregated N-of1 Trials with Parallel and Crossover Randomized Controlled Trials Using Simulation Studies. Healthcare. 2019.42. Mitchell GK, Hardy JR, Nikles CJ, Carmont SAS, Senior HE, Schluter PJ, et al. The effect of methylphenidate on fatigue in advanced cancer: An aggregated N-of-1 trial. J Pain Symptom Manage. 2015.Annelieke Muller sHL.indd 102 14-11-2023 09:07